Area of research
Oncology · Dermatology
Research interest
Research focused on Guideline and Actinic keratosis, with related work in Dermatology, Melanoma, Gynecology. Notable publications include 'Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma', 'S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma – short version, part 1: diagnosis, interventions for actinic keratoses, care structures and...', and 'S3‐Guideline “Diagnosis, therapy and follow‐up of melanoma” – short version'.
Interleukin-4 and -13 Gene Expression Profiles in Immune-Related Bullous Pemphigoid Indicate Efficacy of IL-4/IL-13 Inhibitors
Checkpoint inhibitor–induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression level
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
S3 guideline „actinic keratosis and cutaneous squamous cell carcinoma“ – update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention
S3 guideline „actinic keratosis and cutaneous squamous cell carcinoma“– update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen's disease), occupational disease and structures of care
S3‐Leitlinie “Aktinische Keratose und Plattenepithelkarzinom der Haut“ – Update 2023, Teil 2: Epidemiologie und Ätiologie, Diagnostik, Therapie des invasiven Plattenepithelkarzinoms der Haut, Nachsorge und Prävention
German S3 guideline “actinic keratosis and cutaneous squamous cell carcinoma” – Long version of the update 2023
S3‐Leitlinie “Aktinische Keratose und Plattenepithelkarzinom der Haut“ – Update 2023, Teil 1: Therapie der aktinischen Keratose, Morbus Bowen, Cheilitis actinica, berufsbedingte Erkrankung und Versorgungsstrukturen
S2k‐Guidelines – Cutaneous lymphomas (ICD10 C82 ‐ C86): Update 2021
S2k‐Leitlinie – Kutane Lymphome (ICD10 C82–C86): Update 2021
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
eHealth Literacy in German Skin Cancer Patients
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study
Is there an overtreatment of melanoma patients at the end of their life? Results of a multicenter study on 193 melanoma patients
S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma – short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality‐of‐care indicators
S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) – short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow‐up, prevention and occupational disease
Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional Trial
S3‐Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ – Kurzfassung, Teil 1: Diagnostik, Interventionen bei aktinischen Keratosen, Versorgungsstrukturen und Qualitätsindikatoren
S2k‐Leitlinie – Kutane Lymphome Update 2016 – Teil 2: Therapie und Nachsorge (ICD10 C82 ‐ C86)
Psycho‐oncological care of melanoma patients in certified skin cancer centers
S2k Guidelines – Cutaneous Lymphomas Update 2016 – Part 2: Treatment and Follow‐up (ICD10 C82 ‐ C86)
S2k‐Leitlinie – Kutane Lymphome Update 2016 – Teil 1: Klassifikation und Diagnostik (ICD10 C82 ‐ C86)
Interactions from complementary and alternative medicine in patients with melanoma
S2k Guidelines – Cutaneous Lymphomas Update 2016 – Part 1: Classification and Diagnosis (ICD10 C82 ‐ C86)
Use of complementary and alternative medicine: A multicenter cross-sectional study in 1089 melanoma patients
Risk of interactions between complementary and alternative medicine and medication for comorbidities in patients with melanoma
Aggressive primary cutaneous B‐cell lymphomas show increased Angiopoietin‐2‐induced angiogenesis
Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”
S3‐Guideline “Diagnosis, therapy and follow‐up of melanoma” – short version
Malignes Melanom S3‐Leitlinie “Diagnostik, Therapie und Nachsorge des Melanoms”